熱門資訊> 正文
Corbus Pharmaceuticals GAAP EPS of -$0.90
2024-08-06 21:08
- Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.90.
- The Company reported cash, cash equivalents and investments of $147 million at June 30, 2024.
More on Corbus Pharmaceuticals
- Corbus: Nectin-4 Targeting Proven With U.S. Data On The Way Early 2025
- Wedbush starts Corbus at outperform, citing cancer, obesity drug candidates
- Corbus gains ahead of Goldman Sachs event
- Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals
- Historical earnings data for Corbus Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
